Comparing two blood pressure medicines after childbirth for high blood pressure
Compares labetalol and nifedipine in women with high blood pressure after giving birth.
Key facts
- Who runs it
- Nebraska Methodist Health System
- Where
- Omaha, United StatesSee the site
- Trial code
- Registry title
- Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 600 people, planned
- Started
- 20 Jun 2022
- Planned end
- 1 Dec 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Labetalol Oral Tablet
- NIFEdipine ER
- Record updated
- 12 April 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women admitted to give birth (24 weeks of pregnancy or more) who have high blood pressure. It compares Labetalol with Nifedipine after delivery.
- Age
- 19 years or older
- Sex
- Women only
- Disease stage
- High blood pressure: systolic 140mmHg or higher, or diastolic 90mmHg or higher, on two occasions at least 4 hours apart.
Main reasons for not taking part
- History of moderate persistent asthma, coronary artery disease, heart failure, AV heart block or pulmonary edema
- Cannot take Nifedipine or Labetalol
- Heart rate under 60 or over 110
- Native language other than English or Spanish
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Any patient admitted for delivery by cesarean or vaginal delivery at 24 weeks gestation or greater with hypertension(HTN). Hypertension will be defined during the study as either a systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg on two occasions at least 4 hours apart. This definition is consistent with the ACOG definition for pregnancy related HTN. Following enrollment, treatment will be escalated at discretion of primary provider with the goal of normotension
Who cannot take part
- History of moderate persistent asthma, coronary artery disease, heart failure, AV heart block, pulmonary edema
- Contraindication to either Nifedipine or Labetalol
- HR <60 or >110
- Native language other than English or Spanish
Where in United States
- Nebraska Methodist Women's HospitalOmaha, United StatesContact: Todd LovgrenTaking people
About the trial
What the trial wants to find out
Randomized trial comparing risk of hospital readmission and hypertensive complications between patients managed on Labetalol compared to Nifedipine.
The 2 groups in the trial
- NifedipineExisting treatment, for comparison
Patients randomized to Nifedipine will be started on Nifedipine XR 30mg BID. Escalation in therapy to be determined by primary provider. Maximum dose of Nifedipine is 120mg daily. All patients will be monitored for signs and symptoms of hypotension or medication side effect- severe HA, orthostasis, syncope.
Treatment: NIFEdipine ER
- LabetalolExisting treatment, for comparison
Patients randomized to Labetalol will be started on 200mg TID. Escalation in therapy to be determined by primary provider. Maximum dose is 2400mg in a day. All patients will be monitored for signs and symptoms of hypotension or medication side effect- orthostasis, syncope, bradycardia.
Treatment: Labetalol Oral Tablet
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial
- Plain-language title
- Comparing two blood pressure medicines after childbirth for high blood pressureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 12 April 2024